SAMHD1 rs1291141: What Your Genotype Means
The rs1291141 variant is a single nucleotide polymorphism located within the SAMHD1 gene. Research indicates that this specific variant is associated with clinical outcomes in pediatric patients diagnosed with acute myeloid leukemia (AML).
What each genotype means
Baseline SAMHD1 variant profile
This genotype represents the common form of the rs1291141 variant in the SAMHD1 gene. Research indicates that this variant is associated with clinical outcomes in pediatric acute myeloid leukemia patients, though the specific functional impact remains a subject of ongoing study. Please discuss any concerns regarding leukemia risk or treatment outcomes with your oncologist or a genetic counselor.
The frequency of this genotype varies significantly by ancestry and is observed across diverse global populations.
Heterozygous SAMHD1 variant profile
This genotype indicates you carry one copy of the C allele and one copy of the T allele at this position. This variant has been associated with clinical outcomes in pediatric acute myeloid leukemia patients in scientific literature. As this is a complex trait, please consult with your healthcare provider to understand how this information relates to your personal health history.
This genotype is found at varying frequencies depending on ancestral background, with prevalence data differing between populations.
Alternative SAMHD1 variant profile
This genotype represents the alternative form of the rs1291141 variant. Scientific studies have linked this variant to clinical outcomes in pediatric acute myeloid leukemia patients. Because genetic associations with complex diseases are statistical in nature, please discuss the implications of this finding with your clinician to determine if it is relevant to your medical care.
This genotype is less common in many populations compared to the major allele, with frequency distributions highly dependent on ancestry.
Understanding the rs1291141 Variant
The rs1291141 variant is a specific genetic change, known as a single nucleotide polymorphism (SNP), situated in the 3' region of the SAMHD1 gene. SNPs are the most common type of genetic variation among people, representing a difference in a single DNA building block, or nucleotide. In the context of the SAMHD1 gene, which is located on chromosome 20, this variant has been identified by researchers investigating the genetic factors that influence how pediatric patients respond to cancer treatments. While many SNPs have no effect on health, researchers study these specific variations to determine if they correlate with differences in disease progression or therapeutic response. The identification of rs1291141 as a potential marker is part of a broader effort to understand the pharmacogenomics of leukemia, aiming to provide more personalized insights into clinical outcomes for children undergoing treatment.
The Role of the SAMHD1 Gene
The SAMHD1 gene provides instructions for making an enzyme that plays a critical role in maintaining cellular health. This enzyme functions as a deoxynucleoside triphosphate (dNTP) triphosphohydrolase, which helps regulate the levels of dNTPs—the building blocks required for DNA synthesis and repair. By controlling these levels, SAMHD1 helps ensure that DNA replication proceeds accurately and that the cell can effectively repair damage. Beyond its role in DNA maintenance, SAMHD1 has been identified as a factor in how cancer cells respond to certain chemotherapy drugs, such as cytarabine (Ara-C). In some contexts, the enzyme can break down the active form of these drugs, potentially reducing their effectiveness against leukemic cells. Because of this, the gene is considered a significant area of study for understanding drug resistance and tumor suppression in various malignancies, including acute myeloid leukemia.
Research and Clinical Associations
Scientific research has explored the link between SAMHD1 variants and clinical outcomes in pediatric acute myeloid leukemia (AML). A study published in 2023 evaluated multiple SNPs within the SAMHD1 gene, including rs1291141, using data from pediatric clinical trials. The findings suggested that this variant, along with others in the 3' region of the gene, showed a statistical association with clinical outcomes such as event-free survival and overall survival in the cohorts studied. It is important to note that while these associations are statistically significant in the research setting, the evidence is considered moderate. Further validation in larger, diverse patient populations is necessary to fully understand the clinical utility of this variant. These findings highlight the complexity of cancer genetics, where multiple factors, including both inherited variants and acquired mutations, contribute to how a patient's disease behaves and how they respond to specific medical interventions.
Population Frequency and Interpretation
The frequency of the rs1291141 variant varies significantly across different ancestral populations. Genetic variations are rarely distributed uniformly, and the prevalence of specific alleles can differ based on geographic and ethnic backgrounds. Because of this variability, the potential impact of the variant may not be the same for every individual. When interpreting genetic information, it is essential to recognize that a single SNP is only one piece of a much larger biological puzzle. Factors such as overall genetic background, environmental influences, and the specific characteristics of the disease play major roles in health outcomes. Readers should view this information as educational rather than diagnostic. If you or a family member are dealing with a medical condition like AML, it is vital to discuss all genetic findings and treatment options with a qualified clinician or pharmacist who can provide context based on your specific clinical situation.
How common is this variant?
The frequency of the rs1291141 variant and its associated genotypes varies by ancestry, with no single global frequency applicable to all populations.
Frequently asked questions
What is the SAMHD1 gene?
SAMHD1 is a gene that encodes an enzyme responsible for regulating dNTP levels, which are essential for DNA synthesis and repair. It also acts as a tumor suppressor and plays a role in how cells respond to certain chemotherapy drugs.
Is rs1291141 a diagnostic test for leukemia?
No, rs1291141 is not a diagnostic test. It is a genetic variant studied for its potential association with clinical outcomes in patients already diagnosed with acute myeloid leukemia.
Should I be worried if I have this variant?
Genetic variants are common and do not necessarily indicate a health problem. You should discuss any concerns about your genetic results with a healthcare professional who can interpret them in the context of your overall health.
How does SAMHD1 affect chemotherapy?
Research suggests that SAMHD1 can break down certain chemotherapy drugs like cytarabine, which may reduce their effectiveness in killing cancer cells. Scientists are studying this to better understand drug resistance.
Where can I find more information on this variant?
You can find more information through reputable scientific databases like the GWAS Catalog, PubMed, or ClinVar. Always consult with your doctor or pharmacist regarding medical or treatment-related questions.
Sources & further reading
Educational information only, last refreshed 10/2/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs1291141?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in SAMHD1
This variant in the SAMHD1 gene is significantly associated with event-free and overall survival in pediatric acute myeloid leukemia.
This variant in the SAMHD1 gene is associated with clinical outcomes in pediatric acute myeloid leukemia patients.